202 related articles for article (PubMed ID: 19443248)
1. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer.
Nuñez-Anita RE; Arroyo-Helguera O; Cajero-Juárez M; López-Bojorquez L; Aceves C
Prostaglandins Other Lipid Mediat; 2009 Jun; 89(1-2):34-42. PubMed ID: 19443248
[TBL] [Abstract][Full Text] [Related]
2. 6-iodolactone, key mediator of antitumoral properties of iodine.
Nava-Villalba M; Aceves C
Prostaglandins Other Lipid Mediat; 2014 Aug; 112():27-33. PubMed ID: 25018052
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Faddy HM; Robinson JA; Lee WJ; Holman NA; Monteith GR; Roberts-Thomson SJ
Int J Biochem Cell Biol; 2006 Feb; 38(2):255-66. PubMed ID: 16226051
[TBL] [Abstract][Full Text] [Related]
5. The human semaphorin 6B gene is down regulated by PPARs.
Collet P; Domenjoud L; Devignes MD; Murad H; Schohn H; Dauça M
Genomics; 2004 Jun; 83(6):1141-50. PubMed ID: 15177567
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
Han S; Roman J
Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma in malignant diseases.
Wang T; Xu J; Yu X; Yang R; Han ZC
Crit Rev Oncol Hematol; 2006 Apr; 58(1):1-14. PubMed ID: 16388966
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Aceves C; García-Solís P; Arroyo-Helguera O; Vega-Riveroll L; Delgado G; Anguiano B
Mol Cancer; 2009 Jun; 8():33. PubMed ID: 19500378
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
12. [Effects of different dietary fatty acid on expression of nuclear receptor genes in breast cancer of rats].
Wei N; Mi MT; Wang B; Zhu JD; Zhu DP; Yuan JL
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jul; 41(4):271-6. PubMed ID: 17959046
[TBL] [Abstract][Full Text] [Related]
13. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.
Nava-Villalba M; Nuñez-Anita RE; Bontempo A; Aceves C
Mol Cancer; 2015 Sep; 14():168. PubMed ID: 26376791
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis.
Rösner H; Torremante P; Möller W; Gärtner R
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):410-9. PubMed ID: 19802778
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic effect of iodine and iodide in dimethylbenz[a]anthracene-induced mammary tumors: association between lactoperoxidase and estrogen-adduct production.
Soriano O; Delgado G; Anguiano B; Petrosyan P; Molina-Servín ED; Gonsebatt ME; Aceves C
Endocr Relat Cancer; 2011 Aug; 18(4):529-39. PubMed ID: 21690268
[TBL] [Abstract][Full Text] [Related]
16. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
[TBL] [Abstract][Full Text] [Related]
17. Different modulation of ER-mediated transactivation by xenobiotic nuclear receptors depending on the estrogen response elements and estrogen target cell types.
Min G
Ann N Y Acad Sci; 2006 Dec; 1091():244-57. PubMed ID: 17341619
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
Theocharis S; Margeli A; Vielh P; Kouraklis G
Cancer Treat Rev; 2004 Oct; 30(6):545-54. PubMed ID: 15325034
[TBL] [Abstract][Full Text] [Related]
19. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
Pseftogas A; Gonidas C; Mosialos G
Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
[TBL] [Abstract][Full Text] [Related]
20. Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes.
Murad H; Collet P; Brunner E; Schohn H; Bécuwe P; Devignes MD; Dauça M; Domenjoud L
Biochimie; 2007 Mar; 89(3):329-36. PubMed ID: 17070643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
